AxoGen, Inc. (NASDAQ:AXGN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of AxoGen, Inc. (NASDAQ:AXGN) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $35.5556.

A number of equities analysts have recently weighed in on AXGN shares. HC Wainwright upped their price target on shares of AxoGen from $26.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. Lake Street Capital upped their target price on shares of AxoGen from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. Raymond James Financial reiterated an “outperform” rating and set a $36.00 price target on shares of AxoGen in a research report on Thursday, December 4th. Mizuho began coverage on AxoGen in a research note on Monday, December 1st. They set an “outperform” rating and a $40.00 price target on the stock. Finally, Canaccord Genuity Group upped their price target on AxoGen from $27.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, December 5th.

Insider Buying and Selling

In other news, Director Kathy Johnson Weiler sold 46,653 shares of AxoGen stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $29.55, for a total transaction of $1,378,596.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Amy Mcbride Wendell sold 43,684 shares of the stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $29.31, for a total transaction of $1,280,378.04. Following the completion of the sale, the director directly owned 93,826 shares in the company, valued at approximately $2,750,040.06. The trade was a 31.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 434,143 shares of company stock valued at $11,995,476 in the last three months. 2.78% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of AXGN. Future Financial Wealth Managment LLC purchased a new stake in AxoGen in the 3rd quarter valued at approximately $27,000. Aquatic Capital Management LLC raised its holdings in shares of AxoGen by 287.8% in the third quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock worth $31,000 after acquiring an additional 1,269 shares during the last quarter. State of Alaska Department of Revenue acquired a new position in shares of AxoGen in the third quarter worth $43,000. Tower Research Capital LLC TRC lifted its position in shares of AxoGen by 189.9% in the second quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider’s stock valued at $55,000 after acquiring an additional 3,327 shares in the last quarter. Finally, FNY Investment Advisers LLC acquired a new stake in shares of AxoGen during the third quarter valued at $64,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

AxoGen Stock Performance

NASDAQ AXGN opened at $32.84 on Wednesday. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of -656.80 and a beta of 1.06. The business’s 50 day moving average is $25.39 and its two-hundred day moving average is $17.99. AxoGen has a 12-month low of $9.22 and a 12-month high of $34.24. The company has a current ratio of 4.09, a quick ratio of 2.64 and a debt-to-equity ratio of 0.54.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. The firm had revenue of $60.08 million for the quarter, compared to the consensus estimate of $56.90 million. AxoGen had a negative return on equity of 1.90% and a negative net margin of 0.98%. Research analysts expect that AxoGen will post -0.29 EPS for the current year.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.